These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease. Enomoto Y, Suzuki Y, Hozumi H, Mori K, Kono M, Karayama M, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Suzuki D, Ogawa N, Nakashima R, Mimori T, Iwashita T, Suda T. Arthritis Res Ther; 2017 Jan 19; 19(1):9. PubMed ID: 28103926 [Abstract] [Full Text] [Related]
4. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue. Peng QL, Zhang YL, Shu XM, Yang HB, Zhang L, Chen F, Lu X, Wang GC. J Rheumatol; 2015 Jun 19; 42(6):979-87. PubMed ID: 25877505 [Abstract] [Full Text] [Related]
5. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis. Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Arthritis Care Res (Hoboken); 2016 May 19; 68(5):689-94. PubMed ID: 26414240 [Abstract] [Full Text] [Related]
6. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Chen Z, Cao M, Plana MN, Liang J, Cai H, Kuwana M, Sun L. Arthritis Care Res (Hoboken); 2013 Aug 19; 65(8):1316-24. PubMed ID: 23908005 [Abstract] [Full Text] [Related]
7. Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis. Peng Y, Zhang S, Zhao Y, Liu Y, Yan B. Clin Rheumatol; 2018 Jan 19; 37(1):107-115. PubMed ID: 28842784 [Abstract] [Full Text] [Related]
8. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Shirakashi M, Nakashima R, Tsuji H, Tanizawa K, Handa T, Hosono Y, Akizuki S, Murakami K, Hashimoto M, Yoshifuji H, Ohmura K, Mimori T. Rheumatology (Oxford); 2020 Nov 01; 59(11):3284-3292. PubMed ID: 32276271 [Abstract] [Full Text] [Related]
18. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies. Yamaguchi K, Yamaguchi A, Kashiwagi C, Sawada Y, Taguchi K, Umetsu K, Oshima K, Uchida M, Suzuki M, Kono S, Takemura M, Masubuchi H, Kitahara S, Hara K, Maeno T, Motegi SI, Muro Y, Sakairi T, Hisada T, Kurabayashi M. Respir Med; 2018 Jul 01; 140():1-5. PubMed ID: 29957268 [Abstract] [Full Text] [Related]
19. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis. Zuo Y, Ye L, Liu M, Li S, Liu W, Chen F, Lu X, Gordon P, Wang G, Shu X. Rheumatology (Oxford); 2020 Oct 01; 59(10):2829-2837. PubMed ID: 32065646 [Abstract] [Full Text] [Related]
20. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis. Sakamoto N, Ishimoto H, Nakashima S, Yura H, Miyamura T, Okuno D, Hara A, Kitazaki T, Kakugawa T, Ishimatsu Y, Satoh M, Mukae H. Intern Med; 2019 Mar 15; 58(6):837-841. PubMed ID: 30449789 [Abstract] [Full Text] [Related] Page: [Next] [New Search]